A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
Feng Wang(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Fuxiang Zhou(Wuhan University), Xiangyuan Wu(Zhejiang University), Zengqing Guo(Fujian Provincial Cancer Hospital), Ying Yuan(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhixiang Zhuang(Soochow University), Yanqiao Zhang(Harbin Medical University), Ming-Ming He(Sun Yat-sen University), Shuang-Zhen Chen(Sun Yat-sen University), Wei Wang(First Affiliated Hospital of Wannan Medical College), Xiaohua Hu(Guangxi Medical University), Jian Xiao(Sun Yat-sen University), Xianglin Yuan(Tongji University), Weijia Fang(Zhejiang Cancer Hospital), Ying Guo(Sun Yat-sen University), Qingfeng Zou(Guangzhou Medical University)
Cited by 2
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Demographic history and rare allele sharing among human populations
|Proceedings of the National Academy of Sciences|2011|733